LGND Ligand Pharmaceuticals Incorpor
$311.73▲ +1.11%
Healthcare
Other
After hours
$311.73▲ +0.00%
Oct 27, 4:00 PM ET
Volume 143.3K
Avg Volume (10D) 232.1K
Key Metrics & Fundamentals
Market Cap
$6.21B
P/E Ratio
32.8
Div Yield
0.00%
52W Range
175.89 - 326.63
% vs 50 MA
5.84%
% vs 200 MA
24.28%
RSI-14
57.6
MACD Histogram
+0.5300
Beta (1Y vs SPY)
0.80
Free Cash Flow
$21.35M
Gross Rev
$63.69M
Gross Profit
$60.48M
EBITDA
$26.79M
COGS
$3.21M
Operating Exp
$51.89M
Operating Income
$8.59M
EBIT
$8.59M
Pretax Income
$64.30M
Net Income
$48.51M
EPS (Diluted)
2.22
Price & Volume History
Loading chart…
Recent News
Ligand to Participate in November Investor Conferences
GlobeNewswire · Oct 27, 2026 4:01 PM ET
Ligand to Host Investor Day on December 8, 2026
GlobeNewswire · Oct 22, 2026 4:01 PM ET
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
MT Newswires · Oct 19, 2026 11:42 AM ET
BofA Securities Adjusts Price Target on Ligand Pharmaceuticals to $406 From $388, Maintains Buy Rating
MT Newswires · Oct 19, 2026 8:06 AM ET
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
GlobeNewswire · Oct 15, 2026 7:00 AM ET
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?
Simply Wall St. · Sep 29, 2026 12:04 PM ET
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal
Simply Wall St. · Sep 29, 2026 6:05 AM ET
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
Simply Wall St. · Sep 29, 2026 12:25 AM ET
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
Insider Monkey · Sep 27, 2026 9:08 AM ET
Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls
The Fly · Sep 25, 2026 9:43 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LGND's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.